Endo swallows Paladin for $1.6B

Share this article:

US-headquartered Endo Health Solutions scooped up Montreal-based specialty pharmaceutical company Paladin for $1.6 billion. The companies said in a joint statement Tuesday that while the “New Endo” will embrace both companies on the outside, the companies will have their own turf, with Paladin's current managing team continuing to lead Paladin operations from its Montreal headquarters.

Earnings accompanying the acquisition news showed a 5% decline in sales compared to the same period last year, a decrease which CEO Rajiv De Silva said was not unexpected. The company said in June it was going to overhaul its businesses through a combination of acquisitions, R&D efficiencies and trimming its operating expenses by around $325 million. The shakeup also included the departure of CFO Alan Levin, which was announced in May, and naming De Silva CEO in February.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.